ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Icagen, a drug discovery services firm, will acquire a Sanofi facility near Tucson, Ariz. The 26-year-old facility has its roots as a University of Arizona start-up and offers ultra-high-throughput biology, drug screening, and chemistry capabilities. Icagen will retain a majority of the scientists at the site, many with expertise in synthetic and computational chemistry and in rare disease biology and phenotypic screening. The deal includes a multiyear agreement for Icagen to supply discovery services to Sanofi and manage a Sanofi compound library.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X